Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1

Clinics

Volumn 63, Issue 1, 2008, Pages 39-42

  Cunha, Karin Soares Gonçalves ^a   Barboza, Eliane Porto ^a   Da Fonseca, Eliene Carvalho ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Immunohistochemistry; Puberty; Von recklinghausen's disease

Indexed keywords

EID: 40749127975     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322008000100008     Document Type: Article

References (33)

1. Friedman JM. Neurofibromatosis 1. Clinical Genetics. In:Friedman JM, Gutmann DH, Maccollin M et al, editors Neurofibromatosis. Phenotype, Natural History and Pathogenesis. Baltimore:the Johns Hopkins University Press, 1999, p. 110-8.
2. Geller M, Bonalumi Filho A. Neurofibromatosexlínica, genética e terapêutica. Rio de Janeiro:Guanabara Koogan; 2004.
3. Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in South East Wales. II. Guidelines for genetic counselling. J Med Genet. 1989;26:712-21.
4. Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet.1998;35:813-20.
5. Korf BR. Neurofibromatosis 1. Neurofibromas and malignant tumors of the peripheral nerve sheath. In: Friedman JM, Gutmann DH, Maccollin M, et al, eds. Neurofibromatosis. Phenotype, Natural History and Pathogenesis, Baltimore:the Johns Hopkins University Press;1999, p. 142-61.
6. Korf BR. Plexiform neurofibromas. Am. J Med Genet. 1999;89:31-7.
7. Crawford AH, Schorry EK. Neurofibromatosis update. J Pediatr Orthop. 2006;26:413-23.
8. Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet,1996;66:7-10.
9. Lammert M, Mautner VF, Kluwe L. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC Cancer. 2005;9;5:16.
10. Martuza RL, Maclaughlin DT, Ojemann RG. Specific estradiol binding in schawnnomas, meningiomas and neurofibromas. Neurosurgery. 1981;9:665-71.
11. Chaudhuri PK, Walker MJ, Das Gupta TK, Beatties CW. Steroid receptors in tumors of nerve sheath origin. J Surgical Oncology. 1982;20:205-6.
12. Cunha KS, Barboza EP, Da Fonseca EC. Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1. J Clin Pathol. 2003;56(10):758-63.
13. McLaughlin ME, Jacks T. Progesterone receptor expression in neurofibromas.Cancer Res. 2003;63:752-5.
14. Neurofibromatosis. NIH Consens Statement. 1987;6(12):1-19.
15. Shen HS, Harper, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet. 1996;33:2-17.
16. Klose A, Ahmadian M. R, Shuelke M et al. Selective desactivaron of neurofibromin GAP activity in neurofibromatosis type 1 (NF1). Hum Mol Genet. 1998;7:1261-8.
17. Billestrup N, Hansen JA, Hansen LH, et al. Molecular mechanism of growth hormone signaling. Endocr J. 1998;45:s41-5.
18. Carter-Su C, Rui L, Stofega MR. SH2-B and SIRPJAK2 binding proteins that modulate the actions of growth hormone. Recent Prog Horm Res, 2000;55:293-311.
19. Kopchick JJ, Andry JM. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab, 2000;71:293-314.
20. Alexander L, Appleton D, Hall R Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol. 1980;12:71-9.
21. Andrews GS. Growth hormone and malignancy. J Clin Pathol. 1983;36:935-7.
22. Aktan M, Tanakol R, Nalcaci M, Dilcol G. Leukemia in a patient treated with growth hormone. Endocr J. 2000;47:471-3.
23. Barzilay J, Heatley GJ, Gushing G W. Benign and malignant tumors in patients with acromegaly. Arch Intern Med. 1991;151:1629-32.
24. Bengtsson BA, Edén S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-35.
25. British Prostate Study Group. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostate cancer. Br J Urol. 1979;51:382-9.
26. Emerman JT, Leahy M, Gout PW. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res.1985;17:421-4.
27. Garcia-Caballero T, Mertani H M, Lambert A et al. Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas. Endocrine. 2000;12:265-71.
28. Ginarte M, Garcia-Callabero T, Fernandez-Redondo V et al. Expression of growth hormone receptor in benign and malignant cutaneous proliferative entities. J Cutan Pathol. 2000;27:276-282.
29. Kaulsay K K, Zhu T, Bennett W Lee KO, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology. 2001;142:767-77.
30. Lincoln D T, Sinowatz F, Temmim-Baker L, Baker HI, Kolle S, Waters MJ. Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. Histochem Cell Biol. 1998;109:141-59.
31. Ratner RE, Hare JW. Association of acromegaly and chondrosarcoma. South Med J. 1983;76:1181-82.
32. Watanabe S, Mizuno S, Oshima LH Tsunematsu Y, Fujimoto J, Komiyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol. 1993;6:99-108.
33. Saenger P. Growth hormone in von Recklinghausen's disease:reckless or recommended? J Pediatr. 1998;133:172-4.